# Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia

> **NCT00233454** · PHASE2 · COMPLETED · sponsor: **Jason Robert Gotlib** · enrollment: 26 (actual)

## Conditions studied

- Systemic Mastocytosis, Aggressive (ASM)
- Leukemia, Mast Cell
- Hematological Non-mast Cell Lineage Disease (AHNMD)

## Interventions

- **DRUG:** Midostaurin

## Key facts

- **NCT ID:** NCT00233454
- **Lead sponsor:** Jason Robert Gotlib
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2010-06-18
- **Final completion:** 2011-04-16
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2018-09-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00233454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00233454, "Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00233454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*